linjc16/ctgov huggingface dataset:
Clinical Utility of Rapid CT/NG Testing in the ED

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to: determine the clinical impact of rapid Chlamydia Trachomatis (CT), Neisseria Gonorrhoeae (NG) testing on antibiotic over and under treatment for CT/NG in women evaluated in the Emergency Department (ED) for a Sexually Transmitted Infection (STI). determine the clinical impact of rapid Trichomonas Vaginalis (TV) testing on antibiotic under and over treatment for TV in women evaluated in the ED for an STI evaluate the feasibility of integrating rapid Chlamydia Trachomatis (CT), Neisseria Gonorrhoeae (NG) and TV testing in the Emergency Department setting. To evaluate the impact or rapid CT/NG/TV testing an patient comprehension of Sexually Transmitted Infection diagnosis.

Official Title
-----------------
Clinical Utility of Rapid CT/NG Testing in the ED

Conditions
-----------------
Sexually Transmitted Diseases

Intervention / Treatment
-----------------
* Other: Rapid Testing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The study population includes women between the age of 18 and 50 who present to the ED and are going to receive CT/NG testing in the ED. Exclusion Criteria: Patients will be excluded if they are unable to provide informed consent or are not English speaking.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Rapid Testing/Treatment Group<br>All subjects enrolled in the rapid testing group will receive rapid CT/NG and TV testing in addition to the CT/NG Nucleic Acid Amplification Test (NAAT) and wet mount testing that is currently used in the ED. | Other: Rapid Testing<br> <br> |
| No Intervention: Control<br>All subjects enrolled in the control group will receive CT/NG and TV testing according to the current standard of care for Johns Hopkins ED. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overtreatment rate of CT/NG between the control and interventional groups | Overtreatment is defined as CT/NG negative patients who received antibiotic treatment. | 2 week follow-up |
In Vitro Analysis of Effluent Dialysate Solution From Patients on Peritoneal Dialysis, With the CloudCath Device

Study Overview
=================
Brief Summary
-----------------
A proof-of-concept study of a prototype CloudCath device designed to detect peritonitis using the effluent dialysate from patients undergoing peritoneal dialysis.

Official Title
-----------------
In Vitro Analysis of Effluent Dialysate Solution From Patients on Peritoneal Dialysis, With the CloudCath Device

Conditions
-----------------
Peritoneal Dialysis-associated Peritonitis, End Stage Renal Disease

Intervention / Treatment
-----------------
* Diagnostic Test: Effluent dialysate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males or females with end-stage renal disease on peritoneal dialysis for a minimum of 10 days prior to obtaining the specimen. Specimens shall be leftover (or remnant) from a specimen that has been drained as part of the routine care for the patient. Specimens shall not contain any individually identifiable information from the patient it was obtained from. Exclusion Criteria: Patients providing specimens should not be under the administration of any antibiotics other than those utilized for the treatment of peritonitis. Patients providing specimens should not suffer from a known liver disease or from ovarian or liver cancer. Patients providing specimens should not be under the administration of calcium channel blockers or amlodipine for less than 30 days prior to providing a specimen.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Peritoneal dialysis patients<br>Patients undergoing peritoneal dialysis. Patients may be using either Continuous Ambulatory Peritoneal Dialysis (CAPD), Continuous Cycling Peritoneal Dialysis (CCPD) or Intermittent Peritoneal Dialysis (IPD). | Diagnostic Test: Effluent dialysate<br>* Effluent dialysate samples evaluated for evidence of peritonitis<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Spectral measurements of effluent dialysate solutions | a quantitative analysis of the spectral characteristics of the effluent dialysate solution using a proprietary algorithm and sensing equipment that results in a quantitative CloudCath Score. | immediately post dialysis | 
| Conductivity measurements of effluent dialysate solutions. | a quantitative assessment of conductivity of the effluent dialysate solution using a proprietary algorithm and sensing equipment that results in a quantitative CloudCath Score. | immediately post dialysis |
The Relationship of TV Viewing to Energy Balance in Adults

Study Overview
=================
Brief Summary
-----------------
The specific objectives of this project are to: Investigate the effects of reducing TV viewing time on energy intake, eating behavior, and energy expenditure in overweight or obese adult subjects, thus providing a basis for evaluating if reducing TV viewing time might be a useful adjunct therapy in obesity prevention and treatment Analyze the types of foods eaten in conjunction with TV viewing Determine if there is an association between location of TV and BMI.

Official Title
-----------------
The Effects of Limiting TV Viewing on Diet, Exercise, and Sleep in Overweight and Obese Adults

Conditions
-----------------
Obesity, Overweight

Intervention / Treatment
-----------------
* Behavioral: No TV viewing reduction
* Behavioral: TV viewing reduction


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: BMI between 25-50 Watch at least 3 hours of TV per day or 21 hours per week. Between the ages of 21-65 years. Willing to have study staff enter home several times. Willing to have TV viewing time reduced. Exclusion Criteria: Live greater than 45 minutes from UVM campus. Enrolled in a weight loss study Pregnant or planning to become pregnant during active study protocol. Breastfeeding for 6 months or less.

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>This arm will be experiencing the same protocol as the control group, only their TV viewing time will be reduced. The TV viewing time reduction is the experimental intervention. | Behavioral: TV viewing reduction<br>* In the experimental arm, TV viewing time will be reduced for half of the study protocol time (3-4 weeks of a 6-8 week protocol).<br>|
| Active Comparator: Control<br>The control group will be experiencing the exact protocol; only their TV viewing time will not be reduced. | Behavioral: No TV viewing reduction<br>* In the control group, no intervention will be acted upon. This group will receive the exact same protocol as the intervention group, but with observation only.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Energy Intake |  | Phase I and Phase II | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Energy expenditure |  | Phase I and Phase II |
Comparison of TOFscan and TOF-Watch SX in Pediatric Neuromuscular Function Recovery

Study Overview
=================
Brief Summary
-----------------
Comparison of TOFscan and TOF-Watch SX for monitoring of neuromuscular blockade function in children

Detailed Description
-----------------
TOF ratio of TOFscan when TOF-Watch SX shows TOF ratio 0.7 with rocuronium in children during general anesthesia

Official Title
-----------------
Comparison of TOFscan and TOF-Watch SX in Children

Conditions
-----------------
Neuromuscular Blockade

Intervention / Treatment
-----------------
* Device: TOFscan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients need neuromuscular blockade Exclusion Criteria: contraindication of rocuronium

Ages Eligible for Study
-----------------
Maximum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: TOFscan|comparison of TOFscan over TOF-Watch SX|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| TOF ratio of TOFscan | value of TOF ratio of TOFscan at TOF ratio 0.7 of TOF-Watch SX during neuromuscular function recovery period | intraoperative during anesthesia |
Study of Two Surgical Approaches for Total Hip Arthroplasty

Study Overview
=================
Brief Summary
-----------------
A prospective, comparative, randomized single surgeon study comparing minimally invasive total hip arthroplasty (MIS) via anterior approach to conventional total hip arthroplasty via anterolateral transgluteal approach.

Official Title
-----------------
Prospective, Randomized Study of Two Surgical Approaches for Total Hip Arthroplasty

Conditions
-----------------
Total Hip Arthroplasty

Intervention / Treatment
-----------------
* Procedure: Minimally Invasive Total Hip Arthroplasty
* Procedure: Conventional Total Hip Arthroplasty


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients diagnosed with osteoarthritis of the hip and have decided to undergo total hip arthroplasty Patients willing to sign the consent form Exclusion Criteria: Patient is unwilling to sign the consent form Patient is involved in another study
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br>Minimally invasive total hip arthroplasty | Procedure: Minimally Invasive Total Hip Arthroplasty<br> <br> |
| Active Comparator: 2<br> | Procedure: Conventional Total Hip Arthroplasty<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Evaluate early functional outcomes of two anterior approaches to total hip arthroplasty
Digital Self-Management Program for Medicare Advantage Members With Type 2 Diabetes- Impact on A1c

Study Overview
=================
Brief Summary
-----------------
The Digital Self-Management Program for Medicare Advantage Members with Type 2 Diabetes - Impact on A1c trial is a 26-week long, prospective, intent-to-treat, 2-arm randomized controlled trial that aims to evaluate the impact of the Digital Self-Management Program on A1c levels for individuals with uncontrolled Type 2 diabetes.

Official Title
-----------------
Digital Self-Management Program for Medicare Advantage Members With Type 2 Diabetes- Impact on A1c

Conditions
-----------------
Diabetes Mellitus, Type 2

Intervention / Treatment
-----------------
* Behavioral: Diabetes Self-Management Program


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Humana Medicare Advantage member Type 2 diabetes diagnosis HbA1c levels ≥ 8.0% verified by lab test Exclusion Criteria: Has any of the following conditions: cancer, chronic heart failure, chronic obstructive pulmonary disease, respiratory failure, chronic kidney disease, end stage renal disease, peripheral vascular disease Not fluent in English Humana membership is part of a Full or Global risk arrangement Enrolled in Humana at Home Care Management

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Intervention<br>Diabetes Self-Management Program | Behavioral: Diabetes Self-Management Program<br>* The Diabetes Self-Management Program is a platform that includes a smart meter, access to coaching 24/7, and a mobile app and website that help members manage their diabetes. The program offers diabetes education and coaching delivered entirely through the smart meter and mobile app or website.<br>|
| No Intervention: Control<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from Baseline in A1c at 6 months | Change in A1c from study baseline to study end | Baseline and 6 months |
Importance of CD4+CD25+ly in UC1. Investigation of Difference Between Blood Concentration IL 17, IL 33, Regulatory T ly in Patients With UC and Control Group

Study Overview
=================
Brief Summary
-----------------
Mucosal inflammation in patients with UC is the result of immunosuppression disturbance because decreasing number of regulatory T ly and activation IL 17

Conditions
-----------------
Ulcerative Colitis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: endoscopic confirmed diagnosis Exclusion Criteria: corticosteroid or immunosuppressive therapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 2<br>control group | |
| patients with UC<br>patients with UC, without corticosteroid or immunosuppressive therapy | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
QoL and Adherence to One-pill Once-a-day HAART

Study Overview
=================
Brief Summary
-----------------
Primary objective of the study is: To verify if simplification of the antiretroviral regimen, measured as the reduction of pill burden alone, may affect adherence rate of patients.

Official Title
-----------------
Adherence to a One Pill, Once-a-day Antiretroviral Regimen

Conditions
-----------------
HIV Infection, HIV Infections

Intervention / Treatment
-----------------
* Other: reduced number of pills


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 18 years Informed consent signed Effective ongoing treatment (HIV-RNA < 50 copies/ml) for at least three months Being on a stable HAART regimen based either on two possible drug associations: 3TC/FTC + TDF + EFV FTC/TDF (fixed dose combination) + EFV No previous documented virologic failure Exclusion Criteria: Childbearing or breastfeeding. Women of childbearing potential will be asked to adopt effective contraceptive methods or behaviours Any ongoing grade 4 laboratory abnormality

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Simplified one pill regimen<br>Fixed dose combination of tenofovir + emtricitabine + efavirenz | Other: reduced number of pills<br>* Switch to a fixed dose combination one pill/daily HAART<br>* Other names: tenofovir TDF;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of adherence to HAART |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| QoL (VAS scale) preferences of patients virologic and immunologic outcomes |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
adherence, Qol, virologic efficacy, immunologic efficacy, patients' preference, once-daily, HAART, treatment experienced
A Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Impact of Nystatin on the Development of Oral Irritation in Patients Receiving High Dose Intravenous Interleukin-2

Study Overview
=================
Brief Summary
-----------------
In patients who are receiving intravenous high dose Interleukin-2, patients will be randomized into two groups: group one will receive nystatin swish and swallow immediately before initiation of IL-2, and the second group will receive a placebo. The patients in each group will be monitored and evaluated for differences in the rate and severity of development of oral irritation during treatment. They will also be studied for differences between the two groups in the number of doses of IL-2 taken.

Detailed Description
-----------------
In patients who are receiving intravenous high dose Interleukin-2, patients will be randomized into two groups: group one will receive nystatin swish and swallow immediately before initiation of IL-2, and the second group will receive a placebo. The patients in each group will be monitored and evaluated for differences in the rate and severity of development of oral irritation during treatment. They will also be studied for differences between the two groups in the number of doses of IL-2 taken.

Official Title
-----------------
A Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Impact of Nystatin on the Development of Oral Irritation in Patients Receiving High Dose Intravenous Interleukin-2

Conditions
-----------------
Candidiasis, Oral, Gastrointestinal Diseases, Stomatitis

Intervention / Treatment
-----------------
* Drug: Nystatin


Participation Criteria
=================
Eligibility Criteria
-----------------
All patients enrolled on high dose intravenous interleukin-2 studies in the Surgery Branch of the National Cancer Institute are eligible, except for patients who are receiving adoptively transferred cells (cloned peripheral blood cells). All inclusion criteria as stated in the parent immunotherapy protocol apply: No patients with evidence of oral irritation prior to starting therapy; No patients with any known sensitivity to nystatin; No patients receiving systemic antifungals; No patients with active oral infections. In additional, all exclusion criteria as stated in the parent immunotherapy protocol.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Nystatin|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Mucositis, Oral Candidiasis, Prophylaxis, Stomatitis, Swish and Swallow
Brazilian Diabetes Study: a Type 2 Diabetes Prospective Cohort

Study Overview
=================
Brief Summary
-----------------
Ongoing prospective cohort of type 2 diabetes individuals.

Detailed Description
-----------------
The study population included individuals with type 2 diabetes aged between 40 and 70 years old, living in the metropolitan area of Campinas, Brazil. The volunteers were recruited between 2016 and 2020 through radio, newspaper, television and social media advertisements. A total of 1046 participants were enrolled into the study so far. All participants were firstly invited to an interview with the physician-researcher for medical story register and physical examination. Afterwards, all participants were submitted to the following procedures: blood and urine samples collection, dual-energy X-ray absorptiometry, 6 minutes walk test, hand strength test, bone densitometry test, diabetic polyneuropathy evaluation, advanced glycation end-product measurement, electrocardiogram, echocardiogram, carotid doppler ultrasound, flow-mediated dilation, diabetic retinopathy assessment, ambulatory blood pressure monitoring and cardiac computed tomography for calcium scoring. After full examination, patients were contacted every year for 5 years for endpoints registration. The primary endpoint was a composite of all-cause mortality, myocardial infarction, stroke and myocardial revascularization. Secondary endpoints were end-stage kidney disease requiring dialysis and limb amputation. Study data were collected and managed using REDCap electronic data capture tools.

Official Title
-----------------
Brazilian Diabetes Study: a Type 2 Diabetes Prospective Cohort

Conditions
-----------------
Cardiovascular Diseases, Diabete Mellitus, Coronary Artery Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosed type 2 diabetes Age between 40 and 70 years old Exclusion Criteria: Unconfirmed diagnosis of diabetes Intellectual disability

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| MACE | All cause death, myocardial infarction, stroke, myocardial revascularization | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
diabetes, cardiovascular disease